With comprehensive capabilities spanning payload screening, in vitro and in vivo testing, and DMPK analysis, we ensure tailored solutions for optimizing ADCs at every stage of development. Our goal is to enhance therapeutic efficacy while minimizing off-target effects, driving innovation in next-generation oncology treatments.
ICE Bioscience offers comprehensive DMPK services to support drug discovery and development. We provide ADME profiling, metabolite identification, and tailored assays for small molecules, peptides, and biologics, ensuring high-quality data to optimize drug candidates' safety and efficacy.
ICECP™ cancer cell panel screening allows robust, flexible, and tailored profiling of test agents on 500+ cancer cell lines, encompassing various assays such as 2D proliferation, 3D proliferation, colony formation, and apoptosis, with no assay timeline constraints. For generated drug resistant cell lines, we perform RNA-seq-based bioinformatic analysis to investigate the mechanism. Utilizing our in-house algorithm, we can provide detailed information about differential gene expression, enriched pathway and featured gene profiling.
ICE Bioscience provides services for a broad spectrum of targets which cover different DDR pathways, such as single-strand break (SSB) and double-strand break (DSB). Our integrated service platform can support our clients with all-in-one drug discovery solution, which includes protein production, biochemical assays, functional and cell based assays, and in vivo studies, etc. Together, let's unravel the complexities of DDR.
